Navigation Links
Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
Date:10/10/2007

Phase 1b/2 Study to Explore the Efficacy of Novel Proteasome Inhibitor in

Patients with Relapsed Solid Tumors

SOUTH SAN FRANCISCO, Calif., and SAN ANTONIO, Oct. 10 /PRNewswire/ -- Proteolix, Inc. and South Texas Accelerated Research Therapeutics (START) today announced the enrollment of the first patient in a Phase 1 clinical trial to study Proteolix's investigational drug, carfilzomib (PR-171). START is participating in the study under the leadership of Kyriakos Papadopoulos, M.D., MSc, FCP(SA).

This trial is evaluating single agent carfilzomib, a novel proteasome inhibitor, in patients with recurrent or advanced solid tumors. The Phase 1b portion of the study is a dose-escalation study designed to determine the maximum tolerated dose of carfilzomib administered intravenously in patients with solid tumors. After determining the maximum tolerated dose, additional patients will be enrolled in Phase 2 and stratified according to disease type, including non-small cell lung cancer, small cell lung cancer, ovarian cancer and renal cancer.

"We are very excited about beginning this study in San Antonio. This next generation proteasome inhibitor has shown promising activity in myeloma and will offer a new option to our patients with advanced cancer," said Dr. Papadopoulos.

About Carfilzomib

Carfilzomib is a structurally- and mechanistically-novel proteasome inhibitor that exhibits a high level of selectivity for a single active site in the proteasome with minimal cross reactivity to other protease classes. Carfilzomib has been shown in both preclinical and clinical studies to be well tolerated on intensive daily dosing schedules; in preclinical models, this intensive dosing results in greatly improved efficacy against solid tumors. Phase 1 clinical studies have shown that patients with hematologic malignancies who have relapsed or progressed following multiple therapies can achieve durable anti-tumor responses with ca
'/>"/>

SOURCE Proteolix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Malvern initiates European user group meetings for chemical imaging
2. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
3. Accera, Inc. Announces Open-Label Data from Phase II Study in Alzheimers Disease at International Conference on Prevention of Dementia
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
6. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 ResMed (NYSE: ... infringement action against Chinese medical device manufacturer BMC Medical Co., ... today that BMC,s masks listed below infringe ResMed,s patents, and ... these masks in the United States : ... nasal mask , Willow nasal pillows mask , ...
(Date:12/24/2014)... 23, 2014  Lockton Dunning Benefits, the ... announced the addition of Vice President Kim ... Dunning,s Pharmacy Consulting team, Excelsior Solutions. ... experience to the position.  Most recently, she worked ... Diplomat Specialty Pharmacy, where she has held various ...
(Date:12/24/2014)... and RALEIGH, N.C. , Dec. ... Endo International plc (NASDAQ: ENDP ) (TSX: ... BDSI ) announced today that they have submitted a ... to the U.S. Food and Drug Administration (FDA).  Buprenorphine ... of pain severe enough to require daily, around-the-clock, long-term ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
(Date:12/25/2014)... has updated its blog to provide professional shopping tips on wedding ... at LunaDress.co.uk come with big discounts, up to 80 percent off. ... out to be a most exciting memory and can show off ... to a wedding. On the updated fashion blog, ladies can now ... big day . , Going out with friends to a party ...
(Date:12/25/2014)... risk of burns from fires and cooking accidents increases ... cautious, an expert says. "Between Thanksgiving and New ... coming in with burns," said Dr. Steven Sandoval, medical ... of Stony Brook University Hospital in New York. ... not careful, could quickly turn tragic," Sandoval said in ...
(Date:12/25/2014)... early stage breast cancer patients who undergo chemotherapy and/or ... eventually develop leukemia as a result of their treatment, ... a review of more than 20,000 breast cancer cases ... the risk for developing treatment-related leukemia, though low, is ... frequency of bone marrow cancers such as leukemia is ...
(Date:12/25/2014)... 25, 2014 AngelWeddingDress.com tries its best ... online realm. Today, the business has introduced its new ... prom dress promotion. , The new prom outfits are ... every dress lover. They are specially designed for 2015. ... dresses should visit its website before Jan. 26, ...
(Date:12/25/2014)... “ SmileStix ” was featured on NewsWatch as part of ... applications on the iOS, Android, and Windows markets. Andrew Tropeano, ... app review and shared with viewers how this is an ... saying goes, “A picture says a thousand words.” It’s true. ... single image, because each picture holds a unique and special ...
Breaking Medicine News(10 mins):Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Don't Let Burns Mar Your Holidays 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Angelweddingdress 2015 Prom Dresses Online Now 2Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... go for a walk in areas with four-way intersections and ... a large new study finds. ,The study examined ... what extent urban design guidelines increase walking. ,Only ... reasons for walking — the presence of four-way intersections and ...
... Women wanting to get pregnant should opt for ice creams and ... a study undertook by Jorge Chavarro and colleagues// from Harvard ... conducted in the United States between 1991 and 1999 on 18,555 ... pregnant. Jorge says that a daily serving of low fat or ...
... of the EU has come out with a plan to construct ... with sudden and dangerous outbreaks of animal diseases. , ... as the recent bird flu outbreak, previous foot and mouth disease ... will be setting up this rapid action squad. It will ask ...
... Botox brings relief to a long time migraine sufferer//. ... from migraines so severe that the headaches disrupted her ... with participation in her children's daily activities. ... a UT Southwestern Medical Center plastic surgeon who helped ...
... may pave the way to new methods for studying ... of death in industrialized countries, according to a collaborative ... a molecular channel found in heart muscle cell membranes ... humans, suggesting that understanding how this channel’s activity is ...
... They don't scrape and poke. They massage and hypnotise, ... ,Of course, such behaviour renders their more ... all agree on., ,"We drill just like ... Federal Association of Natural Medicine Dentists. The important steps ...
Cached Medicine News:Health News:Busy Intersections Invite People to Walk More 2Health News:A Combination of Botox and Surgery Cures Migraines 2Health News:A Combination of Botox and Surgery Cures Migraines 3Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 2Health News:Fruit Flies May Pave Way to New Treatments for Age-related Heart Disease 3Health News:Homeopathy and Hypnosis Come to Dentistry 2
Lacrimal Cannulas, 19 g. shaft tapering to 23 g. cannula, straight. Overall length 37.5 mm. 5/box....
Anterior Chamber Needle, 21 g., 8 mm from bend to tip. Overall length 25 mm. 5/box....
Nucleus Hydrodissection Cannula, 25 g. Angled with flattened tip. 7 mm angled shaft with flattened tip for insertion under the capsular flap. Overall length 19 mm. 5/box....
Posterior Capsule Polisher, 21 g. Roughened tip, top port. Overall length 23 mm. 5/box....
Medicine Products: